安旭生物：股东马华祥拟减持不超过120万股

Group 1 - The core point of the announcement is that shareholder Ma Huaxiang plans to reduce his stake in Anxu Bio by up to 120,000 shares, which is approximately 0.94% of the total share capital, due to personal financial needs [1] - As of the announcement date, Ma Huaxiang holds about 14.77 million shares, representing 11.62% of the total share capital of Anxu Bio [1] - The shares to be sold were acquired before the company's initial public offering and will be tradable starting from November 18, 2024 [1] Group 2 - Anxu Bio's revenue for the year 2024 is expected to be entirely derived from the in vitro diagnostic industry, accounting for 100% of its revenue [1] - The current market capitalization of Anxu Bio is 5.3 billion yuan [2]